1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)
PI: Joshua Mooney MD
CRC: Karen Morris PhD 650 497 2929
Status: Currently enrolling qualified patients with IPF who are not taking anti-fibrotic medications (Ofev or Esbriet).
Description: This is a one-year study that includes a study drug/placebo infusions every 3 weeks at Stanford.
Eligibility Criteria: find out more about this trial including eligibility criteria.
NCT#: 03955146
2. A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated with Pulmonary Fibrosis on Long Term Oxygen therapy (Part 1 and Part 2) (REBUILD)
PI: Joshua Mooney MD
CRC: Hanna Gratny, BS
Status: Currently enrolling qualifying patients with a variety of types of ILD who are using supplemental oxygen.
Description: This is a five month study that includes use of inhaled Nitric Oxide/placebo along with oxygen, plus measurements of daily activity levels.
Eligibility Criteria: find out more about this trial including eligibility criteria.
NCT#: 03267108
3. A Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants with IPF (PLIANT 201)
PI: Joshua Mooney MD
CRC: Karen Morris PhD 650 497 2929
Status: Currently enrolling qualifying patients with IPF; current use of anti-fibrotic medications (Ofev or Esbriet) is allowed.
Description: This is a five month study that includes use of inhaled Nitric Oxide/placebo along with oxygen, plus measurements of daily activity levels.
Eligibility Criteria: find out more about this trial including eligibility criteria.
NCT#: 04072315
4. A Randomized, Double-blind, Dose-ranging, Placebo-controlled Phase 2a Evaluation of the Safety, Tolerability and Pharmacokinetics of PLN-74809 in Participants with Idiopathic Pulmonary Fibrosis (IPF) (INTEGRIS-IPF) (PLIANT 201)
PI: Joshua Mooney MD
CRC: Karen Morris PhD 650 497 2929
Status: Currently enrolling qualifying patients with IPF; current use of anti-fibrotic medications (Ofev or Esbriet) is allowed.
Description: This is a five month study that includes use of inhaled Nitric Oxide/placebo along with oxygen, plus measurements of daily activity levels.
Eligibility Criteria: find out more about this trial including eligibility criteria.
NCT#: 04396756
5. Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial (PRECISIONS)
PI: Joshua Mooney MD
CRC: Jeanette Morris BA 650 736 8083
Status: Currently enrolling qualifying patients with IPF; current use of anti-fibrotic medications (Ofev or Esbriet) is allowed.
Eligibility Criteria: find out more about this trial including eligibility criteria.
NCT#: 04300920
6. A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
PI: Rishi Raj MD
CRC: Jeanette Morris BA 650 736 8083
Status: Currently enrolling qualifying patients with IPF or select types of non-IPF ILDs; current use of anti-fibrotic medications (Ofev or Esbriet) is allowed.
Description: this is a 6 month study of an oral drug with monthly study visits to Stanford.
Eligibility Criteria: find out more about this trial including eligibility criteria.
NCT#: 04308681